vs

Side-by-side financial comparison of American Assets Trust, Inc. (AAT) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

American Assets Trust, Inc. is the larger business by last-quarter revenue ($110.6M vs $74.7M, roughly 1.5× Health Catalyst, Inc.). American Assets Trust, Inc. runs the higher net margin — 6.1% vs -121.9%, a 128.0% gap on every dollar of revenue. On growth, American Assets Trust, Inc. posted the faster year-over-year revenue change (1.8% vs -6.2%). Over the past eight quarters, Health Catalyst, Inc.'s revenue compounded faster (-0.0% CAGR vs -0.1%).

Personal Assets Trust is a large British investment trust. The company is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index. The chairman is Iain Ferguson CBE.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

AAT vs HCAT — Head-to-Head

Bigger by revenue
AAT
AAT
1.5× larger
AAT
$110.6M
$74.7M
HCAT
Growing faster (revenue YoY)
AAT
AAT
+8.0% gap
AAT
1.8%
-6.2%
HCAT
Higher net margin
AAT
AAT
128.0% more per $
AAT
6.1%
-121.9%
HCAT
Faster 2-yr revenue CAGR
HCAT
HCAT
Annualised
HCAT
-0.0%
-0.1%
AAT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AAT
AAT
HCAT
HCAT
Revenue
$110.6M
$74.7M
Net Profit
$6.7M
$-91.0M
Gross Margin
Operating Margin
23.4%
-115.3%
Net Margin
6.1%
-121.9%
Revenue YoY
1.8%
-6.2%
Net Profit YoY
-16.3%
-340.3%
EPS (diluted)
$0.08
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AAT
AAT
HCAT
HCAT
Q1 26
$110.6M
Q4 25
$110.1M
$74.7M
Q3 25
$109.6M
$76.3M
Q2 25
$107.9M
$80.7M
Q1 25
$108.6M
$79.4M
Q4 24
$113.5M
$79.6M
Q3 24
$122.8M
$76.4M
Q2 24
$110.9M
$75.9M
Net Profit
AAT
AAT
HCAT
HCAT
Q1 26
$6.7M
Q4 25
$-91.0M
Q3 25
$4.5M
$-22.2M
Q2 25
$5.5M
$-41.0M
Q1 25
$42.5M
$-23.7M
Q4 24
$-20.7M
Q3 24
$16.7M
$-14.7M
Q2 24
$11.9M
$-13.5M
Gross Margin
AAT
AAT
HCAT
HCAT
Q1 26
Q4 25
59.4%
Q3 25
60.5%
52.6%
Q2 25
62.6%
Q1 25
62.0%
Q4 24
61.3%
Q3 24
65.5%
47.5%
Q2 24
63.6%
Operating Margin
AAT
AAT
HCAT
HCAT
Q1 26
23.4%
Q4 25
21.1%
-115.3%
Q3 25
22.6%
-22.9%
Q2 25
24.1%
-46.0%
Q1 25
66.3%
-25.4%
Q4 24
26.5%
-22.0%
Q3 24
30.8%
-17.9%
Q2 24
27.8%
-20.8%
Net Margin
AAT
AAT
HCAT
HCAT
Q1 26
6.1%
Q4 25
-121.9%
Q3 25
4.1%
-29.1%
Q2 25
5.1%
-50.8%
Q1 25
39.2%
-29.9%
Q4 24
-26.0%
Q3 24
13.6%
-19.3%
Q2 24
10.7%
-17.8%
EPS (diluted)
AAT
AAT
HCAT
HCAT
Q1 26
$0.08
Q4 25
$0.06
$-1.29
Q3 25
$0.07
$-0.32
Q2 25
$0.09
$-0.59
Q1 25
$0.70
$-0.35
Q4 24
$0.14
$-0.33
Q3 24
$0.28
$-0.24
Q2 24
$0.20
$-0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AAT
AAT
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$118.3M
$95.7M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$1.1B
$245.8M
Total Assets
$2.9B
$502.6M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AAT
AAT
HCAT
HCAT
Q1 26
$118.3M
Q4 25
$129.4M
$95.7M
Q3 25
$138.7M
$91.5M
Q2 25
$143.7M
$97.3M
Q1 25
$143.9M
$342.0M
Q4 24
$425.7M
$392.0M
Q3 24
$533.0M
$387.3M
Q2 24
$114.9M
$308.3M
Total Debt
AAT
AAT
HCAT
HCAT
Q1 26
Q4 25
$1.7B
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$2.0B
$382.4M
Q3 24
$345.0M
Q2 24
Stockholders' Equity
AAT
AAT
HCAT
HCAT
Q1 26
$1.1B
Q4 25
$1.2B
$245.8M
Q3 25
$1.2B
$331.9M
Q2 25
$1.2B
$347.5M
Q1 25
$1.2B
$376.8M
Q4 24
$1.2B
$365.2M
Q3 24
$1.2B
$355.0M
Q2 24
$1.2B
$357.0M
Total Assets
AAT
AAT
HCAT
HCAT
Q1 26
$2.9B
Q4 25
$2.9B
$502.6M
Q3 25
$2.9B
$587.1M
Q2 25
$3.0B
$616.2M
Q1 25
$3.0B
$891.5M
Q4 24
$3.3B
$858.9M
Q3 24
$3.4B
$813.0M
Q2 24
$3.0B
$691.7M
Debt / Equity
AAT
AAT
HCAT
HCAT
Q1 26
Q4 25
1.48×
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.72×
1.05×
Q3 24
0.97×
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AAT
AAT
HCAT
HCAT
Operating Cash FlowLast quarter
$9.9M
Free Cash FlowOCF − Capex
$9.6M
FCF MarginFCF / Revenue
12.9%
Capex IntensityCapex / Revenue
14.5%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AAT
AAT
HCAT
HCAT
Q1 26
Q4 25
$167.1M
$9.9M
Q3 25
$40.5M
$-464.0K
Q2 25
$49.2M
$-9.0M
Q1 25
$36.9M
$280.0K
Q4 24
$207.1M
$-3.5M
Q3 24
$52.4M
$6.2M
Q2 24
$59.3M
$1.6M
Free Cash Flow
AAT
AAT
HCAT
HCAT
Q1 26
Q4 25
$94.9M
$9.6M
Q3 25
$23.1M
$-719.0K
Q2 25
$28.4M
$-9.2M
Q1 25
$20.4M
$-390.0K
Q4 24
$136.9M
$-3.9M
Q3 24
$28.0M
$5.5M
Q2 24
$43.6M
$1.3M
FCF Margin
AAT
AAT
HCAT
HCAT
Q1 26
Q4 25
86.2%
12.9%
Q3 25
21.1%
-0.9%
Q2 25
26.3%
-11.4%
Q1 25
18.8%
-0.5%
Q4 24
120.7%
-4.9%
Q3 24
22.8%
7.2%
Q2 24
39.3%
1.7%
Capex Intensity
AAT
AAT
HCAT
HCAT
Q1 26
14.5%
Q4 25
65.6%
0.4%
Q3 25
15.9%
0.3%
Q2 25
19.3%
0.3%
Q1 25
15.1%
0.8%
Q4 24
61.9%
0.5%
Q3 24
19.9%
0.9%
Q2 24
14.1%
0.4%
Cash Conversion
AAT
AAT
HCAT
HCAT
Q1 26
Q4 25
Q3 25
8.98×
Q2 25
9.01×
Q1 25
0.87×
Q4 24
Q3 24
3.15×
Q2 24
4.98×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AAT
AAT

Rental income$104.4M94%
Other$6.2M6%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons